FDA 483 - Barbara Ann Karmanos Cancer Hospital - September 19, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Barbara Ann Karmanos Cancer Hospital, a PET drug manufacturer in Detroit, MI, revealed significant deficiencies in production and process controls, quality assurance procedures, and sterility testing practices. The firm failed to prevent microbial contamination, adequately investigate excursions, and ensure proper aseptic manipulation, indicating a high risk of product contamination and compromised drug quality. Issues also included undocumented endotoxin investigations and prolonged sterility sample holding times.
ID · b6587455-9327-4cd8-8b2d-497fb0394e27